CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.
If any GlaxoSmithKline investors were hoping new CEO Emma Walmsley would break with her predecessor and pursue a split-up, they got a rude awakening Wednesday.
With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.
As incoming GlaxoSmithKline CEO Emma Walmsley gets ready to move into the company’s top spot, shareholders have objections—and they center on her pay package.